FDA Pharmacy Compounding Advisory Committee Written-Comment Docket FDA-2025-N-6895 Closes at 11:59 PM ET Tonight Wednesday July 22 With Approximately 1,860 Public Comments Filed on the Seven-Peptide Review (BPC-157, KPV, TB-500, MOTS-c, DSIP/Emideltide, Semax, and Epitalon); Hims Chief Medical Officer Dr. Anant Vinjamoori Confirmed Hims Will Testify at the Thursday July 23 Hearing and Publicly Acknowledged the 'Relatively Sparse Clinical Evidence for These Peptides' While Confirming Hims Plans to Offer the Peptides If the FDA Reclassifies Them
The FDA Pharmacy Compounding Advisory Committee (PCAC) written-comment docket FDA-2025-N-6895 closes at 11:59 PM ET on Wednesday July 22, 2026. Approximately 1,860 public comments have been filed on the seven-peptide review, spanning docket comments from institutional commenters supporting inclusion (Hims & Hers Health among them) and opposing inclusion (PhRMA, Partnership for Safe Medicines, American Pharmacists Association, Public Citizen, Institute for Safe Medication Practices, UC Davis's Paul Knoepfler). Hims Chief Medical Officer Dr. Anant Vinjamoori confirmed Hims will testify at Thursday's July 23 hearing at FDA's White Oak Campus in Silver Spring, Maryland. In pre-hearing remarks, Dr. Vinjamoori said medical providers should be honest about 'the relatively sparse clinical evidence for these peptides' but noted that Hims plans to offer the peptides if the FDA reclassifies them. He also cited nearly a decade of accumulated experience across 'thousands of physicians, close to millions of patients' that in his view supports the peptides' health benefits. FDA career-staff briefing documents recommend against adding any of the seven peptides to the 503A Bulks List. PCAC recommendations are advisory; FDA rulemaking (typically 6-18 months) is required before compounding pharmacies can act on any positive committee recommendation.